NASONEX 24HR ALLERGY
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NASONEX 24HR ALLERGY (NASONEX 24HR ALLERGY).
Glucocorticoid receptor agonist; inhibits inflammatory mediators including cytokines, chemokines, and adhesion molecules; reduces nasal inflammation.
| Metabolism | Minimal hepatic metabolism via CYP3A4; extensive first-pass metabolism; primarily excreted as metabolites in bile and urine. |
| Excretion | Mometasone furoate is predominantly eliminated via biliary/fecal excretion. After intravenous administration, approximately 74% of the dose is recovered in feces and about 8% in urine. The drug undergoes extensive hepatic metabolism, and metabolites are excreted primarily in bile. |
| Half-life | The terminal elimination half-life of mometasone furoate is approximately 5.8 hours. This short half-life supports once-daily dosing for intranasal use, but systemic accumulation is minimal with topical administration. |
| Protein binding | Mometasone furoate is approximately 98-99% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | The volume of distribution (Vd) at steady state is approximately 332 L (about 4.7 L/kg assuming a 70 kg individual). This large Vd indicates extensive tissue distribution and binding to extravascular sites. |
| Bioavailability | Intranasal: The absolute bioavailability of intranasal mometasone furoate is approximately <1% due to extensive first-pass metabolism and low systemic absorption. When administered orally, bioavailability is also negligible (<1%) due to first-pass metabolism. |
| Onset of Action | Intranasal: Onset of action for relief of allergic rhinitis symptoms (e.g., nasal congestion, rhinorrhea) is typically within 12 hours after the first dose, with maximum benefit observed after 1-2 weeks of regular use. |
| Duration of Action | Intranasal: The duration of action supports once-daily dosing. Symptom relief persists for 24 hours after a single dose, but continuous daily use is recommended for optimal control of allergic rhinitis. |
2 sprays (50 mcg/spray) per nostril once daily; total dose 200 mcg/day.
| Dosage form | SPRAY, METERED |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Children 2-11 years: 1 spray (50 mcg) per nostril once daily; total dose 100 mcg/day. |
| Geriatric use | No specific dose adjustment; use standard adult dosing. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NASONEX 24HR ALLERGY (NASONEX 24HR ALLERGY).
| Breastfeeding | Mometasone furoate is excreted in human milk in small amounts; the M/P ratio is unknown. Intranasal administration results in minimal systemic levels. Caution is advised, but benefit likely outweighs risk. |
| Teratogenic Risk | Mometasone furoate (NASONEX 24HR ALLERGY) is an intranasal corticosteroid. Systemic absorption is minimal at recommended doses. Animal studies with high doses showed some teratogenic effects (cleft palate), but human data are limited. First trimester: No well-controlled studies, but low systemic exposure suggests minimal risk. Second and third trimesters: No known fetal risks, but use only if clearly needed. |
■ FDA Black Box Warning
No FDA boxed warning.
| Serious Effects |
["Hypersensitivity to mometasone furoate or any excipients","Untreated localized nasal infection (e.g., herpes simplex)"]
| Precautions | ["Nasal fungal infections; monitor for Candida albicans","Potential for glaucoma and cataracts with long-term use","Risk of adrenal suppression with excessive doses or systemic absorption","May delay wound healing after nasal surgery or trauma","Avoid use in patients with active tuberculosis or untreated infections"] |
Loading safety data…
| Fetal Monitoring | No specific maternal-fetal monitoring required. Monitor for signs of adrenal suppression if used chronically at high doses, though unlikely with nasal administration. |
| Fertility Effects | No known effect on fertility at recommended doses. Animal studies showed no impairment of fertility. |